UCB (OTCMKTS:UCBJF) Shares Gap Up – Still a Buy?

UCB SA (OTCMKTS:UCBJF) gapped up prior to trading on Wednesday . The stock had previously closed at $269.30, but opened at $279.1050. UCB shares last traded at $279.1050, with a volume of 201 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a research report on Monday, December 8th. Morgan Stanley reaffirmed an “overweight” rating on shares of UCB in a research note on Monday, September 8th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, UCB presently has an average rating of “Buy”.

UCB Trading Up 3.6%

The stock’s 50 day moving average is $276.73 and its 200 day moving average is $249.37. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.